Raymond James Financial
CTXR icon

Raymond James Financial’s Citius Pharmaceuticals CTXR Stock Holding History

Raymond James Financial’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-226
Closed -$359 – 5363
2025
Q2 		$359 Buy
+226
New +$207 ﹤0.01% 6711

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Raymond James Financial's CTXR Position: Q3 2025 in Review

Raymond James Financial sold out of Citius Pharmaceuticals (CTXR) in Q3 2025, closing a stake of 226 shares — an estimated $359 sold.

Raymond James Financial first reported a position in CTXR in Q2 2025 and held it in 1 quarter. The position peaked at $359 in Q2 2025. 34 funds tracked by Wall St. Rank hold CTXR as of Q3 2025.

  • Raymond James Financial reported no remaining Citius Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 226 Citius Pharmaceuticals shares in Q3 2025, an estimated $359.
  • Raymond James Financial first reported a position in Citius Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Citius Pharmaceuticals position peaked at $359 in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.